T. Rowe Price Associates’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,365,133
| Closed | -$923M | – | 3100 |
|
|
2021
Q3 | $923M | Buy |
5,365,133
+65,321
| +1% | +$8.54M | 0.09% | 238 |
|
|
2021
Q2 | $665M | Sell |
5,299,812
-58,492
| -1% | -$7.38M | 0.06% | 296 |
|
|
2021
Q1 | $727M | Buy |
5,358,304
+48,538
| +0.9% | +$6.27M | 0.07% | 276 |
|
|
2020
Q4 | $679M | Buy |
5,309,766
+114,393
| +2% | +$13.4M | 0.07% | 275 |
|
|
2020
Q3 | $585M | Buy |
5,195,373
+493,254
| +10% | +$49.1M | 0.07% | 280 |
|
|
2020
Q2 | $448M | Buy |
4,702,119
+644,165
| +16% | +$62.1M | 0.06% | 311 |
|
|
2020
Q1 | $365M | Buy |
4,057,954
+625,211
| +18% | +$48.6M | 0.06% | 306 |
|
|
2019
Q4 | $182M | Buy |
3,432,743
+17,306
| +0.5% | +$789K | 0.02% | 497 |
|
|
2019
Q3 | $135M | Sell |
3,415,437
-358,676
| -10% | -$15.6M | 0.02% | 533 |
|
|
2019
Q2 | $155M | Sell |
3,774,113
-721,300
| -16% | -$29.9M | 0.02% | 522 |
|
|
2019
Q1 | $209M | Sell |
4,495,413
-520,254
| -10% | -$22.8M | 0.03% | 455 |
|
|
2018
Q4 | $218M | Buy |
5,015,667
+255,639
| +5% | +$12.8M | 0.04% | 414 |
|
|
2018
Q3 | $272M | Buy |
4,760,028
+469,236
| +11% | +$23.1M | 0.04% | 404 |
|
|
2018
Q2 | $208M | Buy |
4,290,792
+662,570
| +18% | +$24.1M | 0.03% | 473 |
|
|
2018
Q1 | $142M | Buy |
3,628,222
+443,452
| +14% | +$18.8M | 0.02% | 554 |
|
|
2017
Q4 | $135M | Buy |
3,184,770
+31,151
| +1% | +$1.17M | 0.02% | 550 |
|
|
2017
Q3 | $118M | Sell |
3,153,619
-693,288
| -18% | -$24.1M | 0.02% | 583 |
|
|
2017
Q2 | $117M | Sell |
3,846,907
-56,618
| -1% | -$1.64M | 0.02% | 552 |
|
|
2017
Q1 | $103M | Buy |
3,903,525
+186,646
| +5% | +$4.92M | 0.02% | 595 |
|
|
2016
Q4 | $94.9M | Buy |
3,716,879
+432,113
| +13% | +$13.7M | 0.02% | 615 |
|
|
2016
Q3 | $119M | Buy |
3,284,766
+140,567
| +4% | +$4.66M | 0.02% | 535 |
|
|
2016
Q2 | $107M | Buy |
3,144,199
+197,060
| +7% | +$6.41M | 0.02% | 547 |
|
|
2016
Q1 | $77.8M | Buy |
2,947,139
+17,660
| +0.6% | +$514K | 0.02% | 621 |
|
|
2015
Q4 | $143M | Sell |
2,929,479
-195,522
| -6% | -$7.04M | 0.03% | 466 |
|
|
2015
Q3 | $77.8M | Sell |
3,125,001
-22,642
| -0.7% | -$681K | 0.02% | 641 |
|
|
2015
Q2 | $99.6M | Sell |
3,147,643
-26,692
| -0.8% | -$861K | 0.02% | 602 |
|
|
2015
Q1 | $121M | Sell |
3,174,335
-237,040
| -7% | -$9.43M | 0.03% | 559 |
|
|
2014
Q4 | $133M | Buy |
3,411,375
+176,320
| +5% | +$6.15M | 0.03% | 531 |
|
|
2014
Q3 | $97.8M | Sell |
3,235,055
-36,672
| -1% | -$1.03M | 0.02% | 611 |
|
|
2014
Q2 | $111M | Buy |
3,271,727
+1,427,884
| +77% | +$47.7M | 0.02% | 607 |
|
|
2014
Q1 | $63.6M | Buy |
1,843,843
+1,358,043
| +280% | +$61.3M | 0.01% | 779 |
|
|
2013
Q4 | $19.2M | Buy |
+485,800
| New | +$11.7M | ﹤0.01% | 1107 |
|
T. Rowe Price Associates's XLRN Position: Q4 2021 in Review
T. Rowe Price Associates sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 5,365,133 shares — an estimated $923M sold.
T. Rowe Price Associates first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $923M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- T. Rowe Price Associates reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- T. Rowe Price Associates sold 5,365,133 Acceleron Pharma shares in Q4 2021, an estimated $923M.
- T. Rowe Price Associates first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- T. Rowe Price Associates's Acceleron Pharma position peaked at $923M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.